Onconetix vs Rafael
ONCO and RFL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ONCO and RFL compare
Rafael is the larger company, worth 4.4 times as much as Onconetix ($55.8M against $12.7M).
Rafael grew revenue faster over the last twelve months (−4.7% versus −51.3% for Onconetix).
Onconetix keeps more of each dollar of sales as profit, with a net margin of −1579% compared with −3391% at Rafael.
Rafael scores higher on the StockData Score (5 against 3 for Onconetix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ONCO | RFL |
|---|---|---|
| Size and price | ||
| Market cap | $12.7M | $55.8M |
| Share price | $3.21 | $1.07 |
| Change, 1 year | −99.8% | −15.7% |
| Change, 5 years | −100.0% | −82.4% |
| Beta (5Y) | 4.73 | 0.84 |
| Employees | 12 | 17 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.6× (better) | 63.9× |
| P/B | 0.9× | 0.8× (better) |
| FCF yield | – | −53.7% |
| Growth | ||
| Revenue growth (TTM) | −51.3% | −4.7% (better) |
| Revenue growth, 5Y average | – | 1.7% |
| Profitability | ||
| Gross margin | 80.4% | – |
| Operating margin | −2525% (better) | −3823% |
| Net margin | −1579% (better) | −3391% |
| FCF margin | – | −3431% |
| Return on equity | −105% | −36.9% (better) |
| Return on invested capital | −196% | −61.5% (better) |
| Financial health | ||
| Interest coverage | −52.4× (better) | −100.3× |
| Current ratio | 2.21 | 2.35 (better) |
| Altman Z-score | −12.19 | −2.49 (better) |
| Piotroski F-score | 6 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.7% | 7.5% |
| Held by insiders | 40.3% | 39.2% |
| Insider net buying, 12 months | $8.4K | – |
| Short interest, % of float | 40.6% | 0.92% |
Go deeper
- ONCO stock overview
- ONCO income statement
- ONCO valuation and score
- RFL stock overview
- RFL income statement
- RFL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.